Currently, Latanoprost is available as Xalatan (Latanoprost) from Pfizer, and is now introduced by Teva to fulfil generic prescriptions.
Teva commercial director Kim Innes said this is the company’s inaugural product launch for 2012 and their first day-one patent expiry of the year.
"It’s good for Pharmacy, because patent expiries provide them with the opportunities for increasing margins and keeping costs down,” Innes added.
Headquartered in Israel, Teva is committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.